2015WHO肺癌分类(国外英文资料).docVIP

2015WHO肺癌分类(国外英文资料)Histological changes and controversies in lung cancer of 2015 edition WHOThe 2015 edition of the WHO lung cancer classification method into the genetic information more lung cancer, pay attention to the importance of the classification of lung cancer by immunohistochemistry and molecular diagnosis; reclassified from a multidisciplinary perspective, the integration of surgery, pathology, molecular biology and oncology, radiology and other fields of collective wisdom. The purpose of pathological classification is to expect to answer the nature of lung cancer. However, there is no classification that can encompass all the features of lung cancer. Any version of the classification is phased and requires time baptism. The vitality of pathological classification is to guide the treatment and prognosis, rather than the pathologists attention to the amusement of the morphology. William D. Travis is put forward according to the origin of cell carcinoid, small cell lung cancer and large cell neuroendocrine system in neuroendocrine tumors, a huge controversy, perhaps because it does not seem to change the classification of small cell lung cancer EP, the traditional treatment of IP; but Travis still force opinions, the strength of the implementation of the new association with IARC classification of lung cancer WHO that is hope that the new classification and subsequent integration based on clinical trials of better molecular events? The intention behind it, the new version of lung cancer classification life cycle, the precise role of lung cancer accurate medical treatment, we will wait and see.[major changes outlined]1. emphasizes the use of immunohistochemical IHC to determine tissue typing;2., pay attention to the molecular classification of tumor, especially for patients with advanced lung cancer;3. in accordance with the new classification of IASLC / ATS / ERS lung adenocarcinoma in 2011, special histological classification was made for small biopsies an